SLC16A3 and non-small cell lung carcinoma: Based on the above observations, we immunostained primary NSCLC tissues (designated as P in Table 2) and metastatic brain tissues (designated as M) with or without predicted pathogenic ND mutations4 for MCT4 using a monoclonal antibody.